CTOs on the Move

Minute Molecular Diagnostics

www.m2dx.com

 
Minute Molecular Diagnostics was founded in 2017 as a spinout of the Northwestern University Center for Innovation in Global Health Technology (CIGHT). Comprised of a strong management team with extensive diagnostic industry experience, the company has raised $8 million in funding from the NIH and Diagnostic Industry Executives.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.m2dx.com
  • 1800 Sherman Avenue Suite 504
    Evanston, IL USA
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Minute Molecular Diagnostics raised $21.3M on 04/22/2021

Similar Companies

ViroPharma Incorporated

ViroPharma Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Ocugen

Ocugen Inc.is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19.

C2i Genomics

C2i Genomics is the first company to offer post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor`s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to.

Juventas Therapeutics

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.

Priovant Therapeutics

Priovant Therapeutics is a clinical stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.